Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Rhythm Pharmaceuticals (RYTM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cytokinetics (CYTK)
Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Cytokinetics yesterday and set a price target of $90.00. The company’s shares closed last Friday at $63.19.
According to TipRanks.com, Skor is a 5-star analyst with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $91.62, representing a 41.0% upside. In a report issued on January 27, Barclays also initiated coverage with a Buy rating on the stock with a $87.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Rhythm Pharmaceuticals (RYTM)
In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $150.00. The company’s shares closed last Friday at $102.52.
According to TipRanks.com, Ulz is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rhythm Pharmaceuticals with a $142.38 average price target, representing a 38.5% upside. In a report issued on January 20, Wells Fargo also maintained a Buy rating on the stock with a $145.00 price target.
